Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news By Investing.com

Pfizer’s settlements with Dexcel, Cipla and Hikma extend U.S. exclusivity for Vyndamax to June 1, 2031, versus prior expectations for year-end 2028-2030 and Mizuho’s earlier 2033-2035 view. Mizuho reiterated an Outperform rating on BridgeBio Pharma with a $106 price target, while noting Attruby’s new prescription share is already above 25% and could rise further by mid-2031. Pfizer also declared a $0.43 quarterly dividend, its 350th straight quarterly payout.

Analysis

The incremental value transfer is asymmetric: the extension mostly de-risks the cash flows of the incumbent while compressing the probability that the challenger gets a clean, fast share capture. What matters second-order is not just the deferred generic launch date, but the likely change in physician behavior once generic tafamidis is available — a slower step-up from generic initiation to branded continuation would reduce the effective erosion curve and make the branded asset more durable than simple LOE models imply.

For BBIO, the setup improves because the market tends to underwrite a binary cliff while the real outcome is usually a multi-year glide path. If Attruby is already above 25% new-script share, the key variable is the conversion rate of new starts versus the persistence of established patients; that favors a longer duration of above-consensus growth, particularly into 2031-2033 when payer protocols and specialist habits have had time to normalize around the newer product. The stock should therefore trade less like a near-term binary litigation winner and more like a durable penetration story with expanding operating leverage.

For PFE, the market may be too focused on the headline delay and not enough on the fact that the value destruction is now more visible and more predictable, which can keep the name pinned in a lower multiple regime even as litigation risk falls. The dividend helps floor the equity, but it does not fix the core issue that investors are likely to treat this as a maturity-extension rather than a true growth catalyst. The better read is that the company has bought time, not restored terminal economics.

Contrarian angle: the Street may be overestimating how fast payers and prescribers shift to generic first-line behavior in a specialty disease with meaningful persistence on therapy. If branded continuation proves sticky, the ultimate loser is not just the generic entrant but any model that assumes rapid commoditization. That makes the upside on BBIO more durable than a simple event-driven pop, while PFE’s downside is muted near term but capped by the market’s long-standing skepticism about its growth reset.

Key Decisions for Investors

• Long BBIO vs short PFE in a 3-6 month relative-value pair: BBIO benefits from improving duration of growth, while PFE’s rerating upside is limited; target 10-15% spread capture with litigation headlines as the timing catalyst.
• Add BBIO on pullbacks over the next 1-2 weeks, with a 6-12 month horizon: the market is likely underappreciating persistence of branded share and the slower-than-modeled erosion curve; risk/reward favors upside if new-script share keeps compounding.
• Sell downside puts on PFE or use a put spread into the next 1-2 quarters: the extension reduces immediate tail risk, but upside appears capped; this is a better premium-collection setup than outright long equity.
• If available, pair long BBIO against a basket of generic-drug/commodity-exposure names that rely on rapid substitution assumptions: the thesis is that the market is overpricing speed of commoditization in this indication.
• Watch for a post-event retrace in BBIO after the initial enthusiasm fades; if the stock gives back the headline move without a deterioration in new-prescription data, that is the better entry for a medium-term long.